-
Featured Authors
Archive
- May 2013 (1)
- April 2013 (4)
- March 2013 (3)
- February 2013 (1)
- January 2013 (1)
- October 2012 (2)
- September 2012 (1)
- August 2012 (3)
- June 2012 (4)
- May 2012 (4)
- April 2012 (2)
- March 2012 (2)
- February 2012 (1)
- December 2011 (2)
- October 2011 (3)
- September 2011 (2)
- August 2011 (1)
- July 2011 (1)
- June 2011 (4)
- May 2011 (5)
- April 2011 (4)
- March 2011 (2)
- December 2010 (1)
- September 2010 (1)
- April 2010 (5)
- March 2010 (6)
- February 2010 (1)
- January 2010 (2)
Category Archives: The One-on-One Compass
#BIF2012 Company Snapshot: Chimerix
Our next Company Snapshot for next week’s BIO Investor Forum is Chimerix. They will be presenting on Tuesday, at 1:30pm, and will also be participating in a panel at the event, Choose Your Own Adventure — Late Stage Private Company Decisions on Wednesday. To learn more about the company before you get onsite, continue reading! Company Snapshot What is your company’s lead product or technology? Chimerix’s lead product is CMX001, a novel, broad-spectrum, oral antiviral that inhibits double-stranded Read More >
#BIF2012 Company Snapshot: Profil Institute for Translational Medicine
For the next Company Snapshot for the BIO Investor Forum, we’ve spoken with one of the presenting companies at the event, Profil Institute for Translational Medicine, Inc. To find out more about this organization and what they’re doing for biotech, please read below! You’ll be able to see their presentation onsite, Wednesday 10/10 at 9:30am in the Presidio Room. Company Snapshot What is your company’s lead product or technology? Based on collaborations with biopharma, Read More >
#BIF2012 Company Snapshot: ContraFect Corporation
The BIO Investor Forum is fast approaching! Below you’ll find our first Company Snapshot of one of the event’s presenting companies, ContraFect Corporation. Continue reading to learn more about ContraFect’s product, their strategies, and what you can expect from their company in the coming months. Company Snapshot What is your company’s lead product or technology? ContraFect is a private company developing biotherapeutics for resistant, life threatening infections. Our lead compound, CF-301, is a bacteriophage lysin, Read More >
Some ABCs of PAGs
A lot of people, and especially those who have attended BIO events (such as the BIO CEO & Investor Conference, BIO Investor Forum, and the BIO Business Forum) are familiar with the names Michael J. Fox Foundation, FasterCures, ALS Therapy Development Institute, JDRF, and other non-profit Patient Advocacy Groups, or “PAG’s”. In case you missed them, two blog posts came up from the Michael J. Fox Foundation and FasterCures that we wanted to share. They Read More >
What BIO2012 Meant to Boston and the Netherlands
We came across this recent post in Boston.com about the BIO International Convention and BIO Business Forum. It’s not just a recap of the event, but it’s a specific piece on one company’s goals, connecting Boston with the Netherlands. As you know, the BIO One-on-One Partnering System is open and accessible to attendees well after the conference shuts down and everyone goes home. This allows you to do your follow-up: go through your Inbox, research Read More >
